The FDA has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults with moderate-to-severe acute pain.

End-of-Year Report showcases significant changes in the tax landscape, indicating additional complexity in 2025KING OF PRUSSIA, Pa., Jan. 29, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:VERX) (“Vertex” or the ...

The Vertex drug is a milestone after a long history of unsuccessful efforts to develop painkillers without the addictive potential of opioids.

The initial concept to focus on pain-signaling proteins came out of research involving people with a rare hereditary ...

Nowhere are valuations as extended as in the technology sector, particularly among subscription software stocks. Vertex (NASDAQ:VERX), in particular, has seen its share price double over the past ...

Vertex (VERX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Britain's National Health Service (NHS) will provide a cutting-edge gene therapy that aims to cure sickle cell disease, the National Institute for Health and Care Excellence (NICE) said on Friday.

Charity organisation Sickle Cell Society has described the recommendation as a “major breakthrough” for sickle cell patients.

Friday's edition of Forbes Daily covers the investigation of the deadly plane crash, OpenAI's whopping valuation, sluggish ...

Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public ...

The VERTEX 80/80v optics design allows PEAK flexibility and PEAK instrument performance at the same time. The unique Bruker Optics DigiTect ™ technology ensures PEAK signal-to-noise ratio ...